JP2013507430A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507430A5
JP2013507430A5 JP2012533650A JP2012533650A JP2013507430A5 JP 2013507430 A5 JP2013507430 A5 JP 2013507430A5 JP 2012533650 A JP2012533650 A JP 2012533650A JP 2012533650 A JP2012533650 A JP 2012533650A JP 2013507430 A5 JP2013507430 A5 JP 2013507430A5
Authority
JP
Japan
Prior art keywords
weight
fluticasone propionate
formoterol fumarate
cromolyn sodium
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012533650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507430A (ja
Filing date
Publication date
Priority claimed from GBGB0918149.6A external-priority patent/GB0918149D0/en
Application filed filed Critical
Publication of JP2013507430A publication Critical patent/JP2013507430A/ja
Publication of JP2013507430A5 publication Critical patent/JP2013507430A5/ja
Pending legal-status Critical Current

Links

JP2012533650A 2009-10-16 2010-10-15 改善された医薬エアゾール製剤 Pending JP2013507430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918149.6A GB0918149D0 (en) 2009-10-16 2009-10-16 Improved medicinal aerosol formulation
GB0918149.6 2009-10-16
PCT/EP2010/065573 WO2011045432A1 (en) 2009-10-16 2010-10-15 Improved medicinal aerosol formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015036045A Division JP2015129162A (ja) 2009-10-16 2015-02-26 改善された医薬エアゾール製剤

Publications (2)

Publication Number Publication Date
JP2013507430A JP2013507430A (ja) 2013-03-04
JP2013507430A5 true JP2013507430A5 (https=) 2014-06-19

Family

ID=41462450

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012533650A Pending JP2013507430A (ja) 2009-10-16 2010-10-15 改善された医薬エアゾール製剤
JP2015036045A Pending JP2015129162A (ja) 2009-10-16 2015-02-26 改善された医薬エアゾール製剤
JP2016252909A Active JP6568511B2 (ja) 2009-10-16 2016-12-27 改善された医薬エアゾール製剤
JP2019142684A Active JP7203701B2 (ja) 2009-10-16 2019-08-02 改善された医薬エアゾール製剤
JP2022209895A Pending JP2023026517A (ja) 2009-10-16 2022-12-27 改善された医薬エアゾール製剤
JP2025127827A Pending JP2025148616A (ja) 2009-10-16 2025-07-31 改善された医薬エアゾール製剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015036045A Pending JP2015129162A (ja) 2009-10-16 2015-02-26 改善された医薬エアゾール製剤
JP2016252909A Active JP6568511B2 (ja) 2009-10-16 2016-12-27 改善された医薬エアゾール製剤
JP2019142684A Active JP7203701B2 (ja) 2009-10-16 2019-08-02 改善された医薬エアゾール製剤
JP2022209895A Pending JP2023026517A (ja) 2009-10-16 2022-12-27 改善された医薬エアゾール製剤
JP2025127827A Pending JP2025148616A (ja) 2009-10-16 2025-07-31 改善された医薬エアゾール製剤

Country Status (26)

Country Link
US (3) US20120282189A1 (https=)
EP (3) EP2488158B1 (https=)
JP (6) JP2013507430A (https=)
CN (1) CN102665675B (https=)
AU (1) AU2010305698C9 (https=)
BR (1) BR112012008983A2 (https=)
CA (1) CA2776359C (https=)
CL (1) CL2012000947A1 (https=)
CY (1) CY1116109T1 (https=)
DK (2) DK2488158T3 (https=)
ES (2) ES2973882T3 (https=)
FI (1) FI2881108T3 (https=)
GB (1) GB0918149D0 (https=)
HR (2) HRP20240402T1 (https=)
HU (1) HUE065583T2 (https=)
IL (1) IL219161B (https=)
LT (1) LT2881108T (https=)
MX (1) MX2012004337A (https=)
NZ (1) NZ599901A (https=)
PL (2) PL2881108T3 (https=)
PT (2) PT2881108T (https=)
RS (2) RS53883B1 (https=)
SI (2) SI2881108T1 (https=)
SM (2) SMT202400119T1 (https=)
WO (1) WO2011045432A1 (https=)
ZA (1) ZA201202452B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
TWI495466B (zh) * 2010-09-23 2015-08-11 Intech Biopharm Ltd 用於氣喘之吸入性複方組合物
GB201515310D0 (en) * 2015-08-27 2015-10-14 Jagotec Ag Pharmaceutical composition

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2503962A1 (de) 1975-01-31 1976-08-05 Thomae Gmbh Dr K Spruehbare mittel in suspensionsform zur anwendung auf der haut
FR2420972A1 (fr) 1978-03-31 1979-10-26 Roussel Uclaf Application du peroxyde de thenoyle a titre de medicament
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
DE2914181C2 (de) 1979-04-07 1982-06-16 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren und Vorrichtung zum Trocknen temperaturempfindlicher Güter der Pharma- und Nahrungsmittelindustrie
JPS6135815A (ja) 1984-07-28 1986-02-20 Sanshin Seisakusho:Kk 上部集液式加圧ろ過機に於ける機体内液の脱液方法及び同装置
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
EP0617610B1 (en) * 1991-12-18 1997-03-19 Minnesota Mining And Manufacturing Company Suspension aerosol formulations
DE4321288A1 (de) 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DK0731688T3 (da) 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
MX9707864A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
JP3707107B2 (ja) 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
AU725625B2 (en) 1997-01-30 2000-10-19 Alpenstock Holdings Limited A composition
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
JP4570251B2 (ja) 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
CN1150890C (zh) 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
GB9903759D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
AU2001247123A1 (en) * 2000-07-19 2002-02-05 Aeropharm Technology, Inc. A medicinal aerosol formulation
AU2001278115A1 (en) 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
CA2425035A1 (en) 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI324934B (en) 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
GB0201400D0 (en) 2002-01-22 2002-03-13 Glaxo Group Ltd Novel apparatus and process
EP3384931B1 (en) 2002-03-01 2019-07-24 Chiesi Farmaceutici S.p.A. Formoterol superfine formulation
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP2322243A1 (en) * 2002-08-29 2011-05-18 Cipla Ltd. Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium
US20060193610A1 (en) 2003-07-12 2006-08-31 Jong-Hun Han Aromatic emitting apparatus for using cigarjack
EA200600598A1 (ru) 2003-09-19 2006-08-25 Пенвест Фармасьютикалз Ко. Лекарственные формы замедленного высвобождения
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
GB0918150D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
JP2015036045A (ja) * 2013-08-12 2015-02-23 株式会社泉技研 骨質改善のための超音波音響システム及び超音波音響機器の作動方法

Similar Documents

Publication Publication Date Title
AR130239A2 (es) Método para reducir la cantidad del producto de degradación dp3 durante la vida de estante de una composición farmacéutica en solución para aerosol y uso de una lata de aerosol asociada
JP2017057223A5 (https=)
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
JP2013507430A5 (https=)
ES2391563T5 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
FI2515855T6 (fi) Yhdistelmähoito keuhkoahtaumatautia (copd) varten
CA2477881A1 (en) Formoterol superfine formulation
RU2005108050A (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
JP2019182878A5 (https=)
US20150250713A1 (en) Pharmaceutical Composition
RU2010108640A (ru) Новая комбинация терапевтических агентов
JP2013100317A5 (https=)
SI3096737T1 (en) Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
PE20091672A1 (es) Nueva dosificacion y formulacion
JP2019528316A5 (https=)
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
JP2017513824A5 (https=)
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
HRP20140550T1 (hr) Aerosolna formulacija za copd
FI3500241T3 (fi) Yhdistelmähoito copd:lle
JP2019503997A5 (https=)
JP2015505295A5 (https=)
HRP20150174T1 (hr) Poboljšane medicinske aerosolne formulacije